UNSPSC 51182702: Glimepiride/rosiglitazone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182702 Glimepiride/rosiglitazone is a Commodity code that designates a specific oral antidiabetic pharmaceutical combination product, yet recent state and local solicitations tagged under this code show minimal alignment with the code's nominal scope. The Seminole County, Florida procurement (IFB60459723LAS) sought naloxone and drug deactivation systems for community health—products unrelated to diabetes medication—while the Texas Health and Human Services Commission RFI (HHS0017013) addressed direct-to-manufacturer prescription fulfillment strategy without specifying drug categories. The code appears to see limited recent activity in state and local procurement, and the opportunities on file do not reflect purchasing patterns in the glimepiride/rosiglitazone therapeutic category itself.

The geographic spread across Florida and Texas in these two records offers minimal signal for market concentration or predictable buyer behavior under this code. Issuing bodies include a county health department and a state health agency, but the mismatch between the code's pharmaceutical designation and the actual procurement scope—naloxone distribution and pharmacy supply-chain strategy—suggests either misclassification at posting or an artifact of the coding system that does not reliably track diabetes-medication procurement at state and local level. Firms pursuing this code should verify classification accuracy in RFPs and RFQs before allocating business development resources, as the recent opportunities do not demonstrate sustained demand for this specific medication class.